Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (avab uue akna)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Allikas‎: Cancer 2013;119(21):3784-7.

Indekseeritud‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (avab uue akna)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (avab uue akna)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Allikas‎: Lancet 1989;334(8655):122-4.

Indekseeritud‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (avab uue akna)

Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. (avab uue akna)

Ben-Bassat I, Douer D, Ramot B.

Allikas‎: Eur J Haematol 1990;45(2):86-9.

Indekseeritud‎: PubMed 2209824

https://www.ncbi.nlm.nih.gov/pubmed/2209824 (avab uue akna)

Fibrinolytic inhibitors for cancer-associated bleeding problems. (avab uue akna)

Dean A, Tuffin P.

Allikas‎: J Pain Symptom Manage 1997;13(1):20-4.

Indekseeritud‎: PubMed 9029858

https://www.ncbi.nlm.nih.gov/pubmed/9029858 (avab uue akna)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (avab uue akna)

Ford PA, Grant SJ, Mick R, Keck G.

Allikas‎: J Clin Oncol 2015;33(15):1674-9.

Indekseeritud‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (avab uue akna)

Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. (avab uue akna)

Garewal HS, Durie BG.

Allikas‎: Scand J Haematol 1985;35(5):497-500.

Indekseeritud‎: PubMed 4089529

https://www.ncbi.nlm.nih.gov/pubmed/4089529 (avab uue akna)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (avab uue akna)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Allikas‎: Cancer 2006;107(1):136-40.

Indekseeritud‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (avab uue akna)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (avab uue akna)

Marshall A, Li A, Drucker A, Dzik W.

Allikas‎: Hematol Oncol 2016;34(3):147-53.

Indekseeritud‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (avab uue akna)

Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. (avab uue akna)

Prokopchuk-Gauk O, Brose K.

Allikas‎: Cureus 2015;7(12):e428.

Indekseeritud‎: PubMed 26848417

DOI‎: 10.7759/cureus.428

https://www.ncbi.nlm.nih.gov/pubmed/26848417 (avab uue akna)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (avab uue akna)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Allikas‎: Leuk Lymphoma 1995;19(1-2):141-4.

Indekseeritud‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (avab uue akna)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (avab uue akna)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Allikas‎: Hematol Oncol 2008;26(4):241-6.

Indekseeritud‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (avab uue akna)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (avab uue akna)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Allikas‎: Am J Hematol 2006;81(9):720.

Indekseeritud‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (avab uue akna)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (avab uue akna)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Allikas‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Indekseeritud‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (avab uue akna)

The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. (avab uue akna)

Erduran E, Bahadir A, Mutlu M.

Allikas‎: Eur J Clin Med Oncol 2011;3(5):1-4.

Indekseeritud‎: EMBASE 2012295551

https://www.worldcat.org/title/european-journal-of-clinical-medical-oncology/oclc/645421559&referer=brief_results (avab uue akna)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (avab uue akna)

Franchini M, Veneri D, Lippi G.

Allikas‎: Bone Marrow Transplant 2007;39(12):729-35.

Indekseeritud‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (avab uue akna)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (avab uue akna)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Allikas‎: Am J Hematol 2002;69(3):219-22.

Indekseeritud‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (avab uue akna)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (avab uue akna)

Hsieh A, Cheong I.

Allikas‎: Am J Emerg Med 2007;25(9):1085.e1-2.

Indekseeritud‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (avab uue akna)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (avab uue akna)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Allikas‎: Haemostasis 1996;26 Suppl 1:159-64.

Indekseeritud‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (avab uue akna)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (avab uue akna)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Allikas‎: Med Oncol 2010;27(1):16-9.

Indekseeritud‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (avab uue akna)

Recombinant factor VIIa for bleeding in refractory thrombocytopenia. (avab uue akna)

Vidarsson B, Önundarson PT.

Allikas‎: Thromb Haemost 2000;83(4):634-5.

Indekseeritud‎: PubMed 10780334

https://www.ncbi.nlm.nih.gov/pubmed/10780334 (avab uue akna)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (avab uue akna)

Zver S, Andoljšek D, Černelč P.

Allikas‎: Eur J Haematol 2004;72(6):455-6.

Indekseeritud‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (avab uue akna)

Management of bleeding complications of hematologic malignancies. (avab uue akna)

Green D.

Allikas‎: Semin Thromb Hemost 2007;33(4):427-34.

Indekseeritud‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (avab uue akna)

Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. (avab uue akna)

Harrington DJ, Booth L, Dando N, Cottingham L, Beynon T.

Allikas‎: Int J Lab Hematol 2013;35(4):457-9.

Indekseeritud‎: PubMed 23216984

DOI‎: 10.1111/ijlh.12035

https://www.ncbi.nlm.nih.gov/pubmed/23216984 (avab uue akna)

Management of bleeding in patients with advanced cancer. (avab uue akna)

Pereira J, Phan T.

Allikas‎: Oncologist 2004;9(5):561-70.

Indekseeritud‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (avab uue akna)

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (avab uue akna)

Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F.

Allikas‎: Haematologica 1997;82(5):584-7.

Indekseeritud‎: PubMed 9407726

https://www.ncbi.nlm.nih.gov/pubmed/9407726 (avab uue akna)

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (avab uue akna)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Allikas‎: Bull Cancer 2006;93(2):E7-12.

Indekseeritud‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (avab uue akna)